Medical Oncologist
ER-positive breast cancer
ESR1 Mutation: — Why Your Hormone Therapy Stopped Working
An ESR1 mutation means your cancer has found a way around aromatase inhibitors. A blood test can detect it, and a newer class of drugs called selective estrogen receptor degraders — SERDs — is designed specifically to work against it.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- An acquired change, not inherited — ESR1 mutations develop during treatment. They are not the mutation you were born with and are not passed to your children.
- Detected by a blood test — A liquid biopsy — a standard blood draw — finds ESR1 mutations circulating in the bloodstream without requiring a new surgical biopsy.
- A different drug class is needed — Aromatase inhibitors work by lowering oestrogen. An ESR1 mutation makes the cancer active without oestrogen, which is why AIs stop working.
- Testable at cancer centres across India — ESR1 testing is available and can guide what your oncologist recommends for the next stage of treatment.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
An ESR1 mutation develops in ER-positive breast cancer during aromatase inhibitor treatment. It makes the oestrogen receptor active without needing oestrogen, so AIs stop working. NCCN and ASCO guidelines recommend testing for it when metastatic ER-positive cancer progresses, because a drug class called SERDs — selective estrogen receptor degraders — is designed to work against this change.
What is an ESR1 mutation and why does it matter?
ESR1 is the gene that encodes the oestrogen receptor — the protein that oestrogen attaches to in hormone-sensitive breast cancer cells. Aromatase inhibitors work by cutting off the oestrogen supply, which starves the receptor.
An ESR1 mutation changes the receptor so that it switches itself on permanently, without waiting for oestrogen to arrive. When that happens, lowering oestrogen does nothing to slow the cancer.
This mutation is not something you were born with. It develops inside tumour cells under the pressure of aromatase inhibitor treatment — the cancer adapting to survive the drug. Finding it is useful because it points directly to the drug class most likely to work next.
What should I do if my oncologist mentions an ESR1 mutation?
- Ask whether ESR1 testing has been done or is plannedIf your cancer has progressed on an aromatase inhibitor and no ESR1 test has been ordered, ask specifically. A blood draw is usually all that is needed.
- Ask what a positive result means for your next treatmentA positive ESR1 result changes the list of options your oncologist will consider. Ask which drug class is being recommended and why.
- Ask when your result will be readyLiquid biopsy results typically take one to two weeks. Ask for a clear timeline so you are not waiting without one.
- Tell your team everything you are takingSome herbal supplements and traditional medicines affect how hormone-pathway drugs work. List everything, including home remedies, before your appointment.
- Keep a written record of every treatment you have hadThe sequence of treatments matters for choosing what comes next. A written list saves time at every consultation and avoids confusion.
How do doctors find out if you have an ESR1 mutation?
The standard test is a liquid biopsy — a blood draw that detects fragments of tumour DNA circulating in the bloodstream. It does not require a new tissue biopsy or surgery.
The laboratory looks for specific changes within the ESR1 gene. Results are usually available within one to two weeks of the sample reaching the laboratory.
In some cases, tissue from a recent biopsy is tested instead of, or alongside, the blood sample. Your oncologist will recommend whichever approach gives the clearest result for your situation.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Which drug classes are used when an ESR1 mutation is found?
Aromatase inhibitors — letrozole, anastrozole, exemestane — are the drugs the ESR1 mutation renders less effective. Your oncologist will move to a different approach once the mutation is confirmed.
Selective estrogen receptor degraders, or SERDs, work differently from aromatase inhibitors. Instead of cutting off oestrogen, they attach to the oestrogen receptor itself and mark it for destruction by the cell. Because they act directly on the receptor, they can block it even when an ESR1 mutation is switching it on without oestrogen. Elacestrant is an oral SERD that NCCN and ASCO guidelines include as an option specifically for ESR1-mutated metastatic ER-positive, HER2-negative breast cancer after prior endocrine therapy. Fulvestrant is an older injectable SERD in the same class.
CDK4/6 inhibitors — palbociclib, ribociclib, abemaciclib — act on the cell cycle rather than the oestrogen receptor and are sometimes used alongside endocrine agents at this stage. Your oncologist will decide which combination fits your treatment history and current disease status.
What do most families want to know about ESR1 mutations?
Does an ESR1 mutation mean my cancer is more aggressive?
Not necessarily. An ESR1 mutation is a marker of acquired resistance to a specific drug class. It tells you the tumour has adapted to aromatase inhibitors — not that it has become more dangerous in a general sense. What it does mean is that staying on the same aromatase inhibitor is unlikely to help, and a change in treatment strategy is warranted. Your oncologist will reassess the full picture, including recent imaging, to understand how the disease is behaving overall.
What is elacestrant and can I get it in India?
Elacestrant is an oral selective estrogen receptor degrader approved by the US FDA specifically for ESR1-mutated ER-positive, HER2-negative metastatic breast cancer after prior endocrine therapy. It is taken as a daily tablet rather than by infusion. Availability in India is subject to CDSCO approval and import access, and the situation is evolving. Ask your oncologist directly what is currently accessible at your centre and whether any patient-access programs apply to your situation — this is the most reliable way to get an accurate, current answer.
Can I still use CDK4/6 inhibitors after an ESR1 mutation?
CDK4/6 inhibitors target the cell cycle rather than the oestrogen receptor pathway directly, so an ESR1 mutation does not automatically make them ineffective. Whether they remain part of your treatment plan depends on whether you have already used them and what combination your oncologist recommends at this stage. In some cases they are continued alongside a different endocrine agent; in others, the approach changes more substantially. NCCN guidance addresses the sequencing of these agents in metastatic ER-positive disease and your oncologist will apply it to your specific history.
My mother has breast cancer too — should she be tested for ESR1?
ESR1 mutations found during treatment are acquired mutations. They develop in cancer cells under the pressure of treatment and are not present in normal cells, which means they cannot be inherited and are not relevant to your relatives' cancer risk. The mutations that run in families — such as BRCA1 and BRCA2 — are a completely separate category, tested through a different process called germline genetic testing on a different kind of sample. If family history is a concern, tell your relative's oncologist so they can advise on the right kind of testing for them.
Why was ESR1 not tested when I was first diagnosed?
ESR1 mutations are almost always absent at the time of first diagnosis. They develop during treatment, typically after months to years on aromatase inhibitors, as the tumour adapts under treatment pressure. Testing at diagnosis would rarely find the mutation, so it is not routinely done then. The test becomes relevant when metastatic ER-positive cancer progresses on an aromatase inhibitor, because that is the point at which the mutation is most likely to have developed and at which a positive result would directly change what your oncologist recommends next.
What if my ESR1 test comes back negative?
A negative result means this resistance mechanism has not been detected at this point in time. It does not mean the cancer cannot be treated — it means ESR1 mutation is not the reason the current treatment is not working, and your oncologist will look at other explanations and other options. Cancer can develop resistance through more than one pathway. A negative ESR1 result is a piece of information that helps narrow down the next step rather than one that closes treatment pathways.
Did you know?
ESR1 mutations are almost always absent at first diagnosis and develop specifically during treatment with aromatase inhibitors.
This means the mutation is a direct record of how the tumour has responded to treatment — and a signal that the treatment approach needs to change, not that options have run out.
Source: NCCN Guidelines for Breast Cancer and ASCO Educational Book
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What does ESR1 mutation positive mean in breast cancer?
It means a specific change has been detected in the gene that controls how the oestrogen receptor behaves inside cancer cells. The mutated receptor switches itself on without needing oestrogen, so aromatase inhibitors — which work by reducing oestrogen — stop being effective. A positive result is not a sentence: it is information that tells your oncologist which drug class to consider next. NCCN and ASCO guidelines both address ESR1 mutation as a specific decision point in the treatment of metastatic ER-positive breast cancer.
Is an ESR1 mutation hereditary?
No. ESR1 mutations found in breast tumours during treatment are acquired mutations — they develop in cancer cells and are not present in your normal cells. They cannot be inherited and cannot be passed to your children. The mutations associated with inherited breast cancer risk, such as BRCA1 and BRCA2, are a completely different category tested through germline genetic testing on a blood or saliva sample. If inherited risk concerns you or your family, ask your oncologist about a referral for germline genetic counselling — it is a separate question from ESR1.
How long does an ESR1 blood test take?
A liquid biopsy for ESR1 mutation typically returns results within one to two weeks of the sample reaching the laboratory. The blood draw itself takes a few minutes and does not require fasting or hospital admission. Ask your oncologist's team exactly when the sample is being sent and when you should expect the result, so you have a clear timeline. If results are taking longer than expected, call and ask rather than waiting without information.
What is the difference between a SERD and an aromatase inhibitor?
Aromatase inhibitors — such as letrozole and anastrozole — lower oestrogen levels in the body. They work well when the oestrogen receptor only switches on in response to oestrogen. Selective estrogen receptor degraders, or SERDs, work differently: they bind directly to the oestrogen receptor and signal the cell to break it down. Because they act on the receptor itself rather than on oestrogen levels, SERDs can block the receptor even when an ESR1 mutation is making it permanently active. This is why SERDs are specifically considered after an ESR1 mutation is confirmed.
Can my ESR1 mutation be addressed at CION?
CION oncologists assess biomarker results including ESR1 mutation and advise on the treatment pathway that applies. Where endocrine therapies are indicated and accessible, they are administered as day care at CION centres. Availability of specific newer agents in India is subject to CDSCO approval and current access routes; your oncologist will tell you what is accessible at your centre. CION does not provide CAR-T or cell therapy — if that is ever being discussed for you, you would be referred to a centre that offers it.
Does finding an ESR1 mutation mean I have run out of treatment options?
No. An ESR1 mutation signals resistance to one drug class — aromatase inhibitors — and points toward a different class that is designed to address it. It redirects the treatment path rather than ending it. NCCN and ASCO guidelines describe specific treatment sequences for metastatic ER-positive disease after an ESR1 mutation is identified. No single test result tells you how much treatment time lies ahead — that depends on many factors, and it is a conversation worth having directly with your oncologist.